Organon & Co. OGN
Organon & Co. (NYSE: OGN) is an endocrine/women's health drug developer. Its lead program, Miudella, is marketed for contraception (hormone-free copper IUD). Its next catalyst on record is Miudella: U.S. commercial launch (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Miudella — U.S. commercial launch (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Miudella | contraception (hormone-free copper IUD) | device-combination | Approved |
| Nexplanon | contraception (subdermal implant) | device-combination | Approved |
| Pyzchiva (ustekinumab biosimilar) | autoimmune/autoinflammatory conditions | antibody | Approved |
| Epyztek | unclear (biosimilar) | biologic-other | Approved |
| Bildyos/Bilprevda (denosumab biosimilar) | bone loss (Prolia/Xgeva biosimilar) | antibody | Approved |
| Hadlima (adalimumab biosimilar) | autoimmune/autoinflammatory conditions | antibody | Approved |
| Renflexis (infliximab biosimilar) | autoimmune conditions | antibody | Approved |
| Ontruzant (trastuzumab biosimilar) | HER2+ breast/gastric cancer | antibody | Approved |
| Brenzys (etanercept biosimilar) | inflammatory diseases | biologic-other | Approved |
| Vtama | plaque psoriasis, atopic dermatitis | small molecule | Approved |
| Emgality | migraine prevention | antibody | Approved |
| NuvaRing | contraception (vaginal ring) | device-combination | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.